Effect of Zerumbone-loaded nanostructured lipid carrier on canine mammary gland tumour cell line

Zerumbone (ZER) from the rhizomes of the wild ginger, Zingiber zerumbet (L.) Smith, is a natural dietary lipophilic compound with antitumour, antiinflammatory, antioxidant, antimicrobial, antinociceptive, hepatoprotective and immunomodulatory properties. However, therapeutic application of zerumbone...

Full description

Bibliographic Details
Main Author: Foong, Jia Ning
Format: Project Paper Report
Language:English
Published: 2015
Online Access:http://psasir.upm.edu.my/id/eprint/83395/
http://psasir.upm.edu.my/id/eprint/83395/1/FPV%202015%2013%20IR.pdf
_version_ 1848859529871097856
author Foong, Jia Ning
author_facet Foong, Jia Ning
author_sort Foong, Jia Ning
building UPM Institutional Repository
collection Online Access
description Zerumbone (ZER) from the rhizomes of the wild ginger, Zingiber zerumbet (L.) Smith, is a natural dietary lipophilic compound with antitumour, antiinflammatory, antioxidant, antimicrobial, antinociceptive, hepatoprotective and immunomodulatory properties. However, therapeutic application of zerumbone is plagued by poor water-solubility and subsequent poor absorption, bioavailability and delivery to target tissues. To overcome this limitation, ZER was loaded into nanostructured lipid carrier (NLC) (ZER-NLC). In this study the anticancer effect of ZER-NLC was determined on a canine mammary gland tumour (CMT-stylo) cell line. It is postulated that loading of ZER into NLC does not compromise the anticancer properties ZER. Using the MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) assay, the proliferation of CMT-stylo cells after treament with 1.7 mM of ZER was at 64.30±9.87, 42.06±9.00, 37.81±10.04% while with 1.8 mM ZER-NLC at 102.77±12.68, 38.42±9.16, 41.13±11.72% after 24, 48 and 72 hr treatment, respectively. The half maximal lethal dose (LD50) for ZER and ZER-NLC at 72 hr was 100 and 90 μM, respectively. The half maximal growth inhibition dose (GI50) for ZER and ZER-NLC after 72 hr treatment was 20 and 25 μM, respectively. The anticancer effect of ZER and ZER-NLC was also visualised using the acridine orange/propidium iodide double staining method. Zerumbone and ZER-NLC induced apoptosis of CMT-stylo cells as shown by the membrane blebbing, nucleus margination and chromatin condensation. This study, for the first time, shows that ZER-NLC is a potentially effective drug delivery system for the treatment of canine mammary gland tumours. The ZER-NLC is innovative, novel, and safe, for cancer therapy.
first_indexed 2025-11-15T12:30:48Z
format Project Paper Report
id upm-83395
institution Universiti Putra Malaysia
institution_category Local University
language English
last_indexed 2025-11-15T12:30:48Z
publishDate 2015
recordtype eprints
repository_type Digital Repository
spelling upm-833952020-09-17T04:14:45Z http://psasir.upm.edu.my/id/eprint/83395/ Effect of Zerumbone-loaded nanostructured lipid carrier on canine mammary gland tumour cell line Foong, Jia Ning Zerumbone (ZER) from the rhizomes of the wild ginger, Zingiber zerumbet (L.) Smith, is a natural dietary lipophilic compound with antitumour, antiinflammatory, antioxidant, antimicrobial, antinociceptive, hepatoprotective and immunomodulatory properties. However, therapeutic application of zerumbone is plagued by poor water-solubility and subsequent poor absorption, bioavailability and delivery to target tissues. To overcome this limitation, ZER was loaded into nanostructured lipid carrier (NLC) (ZER-NLC). In this study the anticancer effect of ZER-NLC was determined on a canine mammary gland tumour (CMT-stylo) cell line. It is postulated that loading of ZER into NLC does not compromise the anticancer properties ZER. Using the MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) assay, the proliferation of CMT-stylo cells after treament with 1.7 mM of ZER was at 64.30±9.87, 42.06±9.00, 37.81±10.04% while with 1.8 mM ZER-NLC at 102.77±12.68, 38.42±9.16, 41.13±11.72% after 24, 48 and 72 hr treatment, respectively. The half maximal lethal dose (LD50) for ZER and ZER-NLC at 72 hr was 100 and 90 μM, respectively. The half maximal growth inhibition dose (GI50) for ZER and ZER-NLC after 72 hr treatment was 20 and 25 μM, respectively. The anticancer effect of ZER and ZER-NLC was also visualised using the acridine orange/propidium iodide double staining method. Zerumbone and ZER-NLC induced apoptosis of CMT-stylo cells as shown by the membrane blebbing, nucleus margination and chromatin condensation. This study, for the first time, shows that ZER-NLC is a potentially effective drug delivery system for the treatment of canine mammary gland tumours. The ZER-NLC is innovative, novel, and safe, for cancer therapy. 2015-02 Project Paper Report NonPeerReviewed text en http://psasir.upm.edu.my/id/eprint/83395/1/FPV%202015%2013%20IR.pdf Foong, Jia Ning (2015) Effect of Zerumbone-loaded nanostructured lipid carrier on canine mammary gland tumour cell line. [Project Paper Report]
spellingShingle Foong, Jia Ning
Effect of Zerumbone-loaded nanostructured lipid carrier on canine mammary gland tumour cell line
title Effect of Zerumbone-loaded nanostructured lipid carrier on canine mammary gland tumour cell line
title_full Effect of Zerumbone-loaded nanostructured lipid carrier on canine mammary gland tumour cell line
title_fullStr Effect of Zerumbone-loaded nanostructured lipid carrier on canine mammary gland tumour cell line
title_full_unstemmed Effect of Zerumbone-loaded nanostructured lipid carrier on canine mammary gland tumour cell line
title_short Effect of Zerumbone-loaded nanostructured lipid carrier on canine mammary gland tumour cell line
title_sort effect of zerumbone-loaded nanostructured lipid carrier on canine mammary gland tumour cell line
url http://psasir.upm.edu.my/id/eprint/83395/
http://psasir.upm.edu.my/id/eprint/83395/1/FPV%202015%2013%20IR.pdf